Corindus Vascular Robotics Inc
Corindus Vascular Robotics — Investor Presentation (March 2017)
21 slides from Corindus Vascular Robotics's investor presentation, Mar 8, 2017
Slide 1: Precision Vascular Robotics
1 Precision Vascular Robotics Corindus Vascular Robotics (CVRS) March 2017
Slide 2: Forward Looking Statements
Forward Looking Statements THIS PRESENTATION CONTAINS “FORWARD - LOOKING STATEMENTS” (AS SUCH TERM IS DEFINED IN SECTION 27 A OF THE SECURITIES ACT OF 1933 , AS AMENDED, AND SECTION 21 E OF THE SECURITIES EXCHANGE ACT OF 1934 , AS AMENDED), AND INFORMATION RELATING TO THE COMPANY, THAT ARE BASED ON
Slide 3: Robotics Market
Robotics Market 3 Robotics market expected to double in 4 years to $135B Source: International Data Corporation Auto - Driving Cars Robotics in Manufacturing 2015 2019 $135 $71 Robotics Market (Billions) Robotics in Healthcare Robots in Hazardous Areas
Slide 4: Global Medical Robotics Market
Global Medical Robotics Market 4 Healthcare s ector expected to grow fastest >30 companies developing robotic technologies 1 st Surgical Robot for general laparoscopic procedures Surgical robot with enhanced information for decision making Orthopedics – Spine surgery Orthopedics 1 st robotic system
Slide 5: Large & Growing Worldwide Market Opportunity
1 Market opportunity assessment based on market research reports and Corindus estimate 2 Peripheral Vascular includes lower limb, carotid, renal, iliac and AAA (abdominal aortic aneurysm) procedures 3 Millennium Research Group Interventional Market Opportunity Large & growing worldwide market • $4.5
Slide 6: Corindus Today
Corindus Today A leader in vascular robotics LARGE Market Opportunity with Long GROWTH Runway $4.5B 1 market opportunity in 2018 driven by over 2.5 million coronary and 3 million non - coronary procedures performed per year DIFFERENTIATED Technology ONLY FDA cleared robotic platform for percutaneous
Slide 7: Recent Milestones
Recent Milestones 7 CAPITAL RAISE $45 MILLION ▪ Expected to close March 15, 2017 ▪ New investors included BSX, BioStar Ventures, Consonance Capital, and Hudson Executive Capital ▪ Royal Philips and HealthCor Partners Management also participated STRATEGIC AGREEMENT Expansion to Japan ▪ Japan Medical
Slide 8: New Leadership & Strengthening Team
New Leadership & Strengthening Team Building operational & clinical excellence Mark Toland President & CEO 20 Year Medical Device Veteran J. Aaron Grantham, MD Chief Medical Officer Practicing Interventional Cardiologist Marty Leon, MD Executive Advisor Interventional Cardiology Thought Leader Campb
Slide 9: Traditional PCI vs CorPath Robotic PCI
Struggle to see angiography Assess Anatomy Close proximity ergonomic visualization Trial & error, wire spinning Navigate Precise ‘Point & Shoot’ predictability ‘Eyeball’ estimate Measure Anatomy Robotic - assisted sub - mm Measurement Manual adjustment Position Stent 1mm precise positioning Devices
Slide 10: CorPath Clinical Benefit
CorPath Clinical Benefit 10 Bedside improvements to enhance workflow Open architecture Potential to improve patient outcomes Evidence of success in complex PCI 1mm movements for precise positioning Sub mm measurement to select the most appropriate stent Reduce stent utilization Radia
Slide 11: CorPath Technology Evolution
CorPath Technology Evolution 11 Generational improvements will fuel growth ▪ 45 Systems Placed ▪ Demonstrated safety & efficacy ▪ Significant reduction in physician radiation exposure ▪ Precise robotic movement ▪ 25 - 50% of cases could be done with system ▪ Increased speed and efficiency* ▪ More ph
Slide 12: The Next Generation is Here: CorPath GRX System
The Next Generation is Here 12 CorPath GRX System * Compared to the CorPath 200 System IMPROVED WORKFLOW FOR BEDSIDE USER* • Extended reach arm • Bedside touchscreen for step - by - step instructions INCREASED PROCEDURAL CONTROL FOR PHYSICIAN* • Active Guide Catheter Management • 40’’ Power Vision M
Slide 13: Building Robust Robotic Programs
Building Robust Robotic Programs Driving strategic growth 13 Commercial Focus on Developing New Programs and Growing Adoption Team Approach Commitment to Building a Program Ongoing Training Adequate Procedural Volume Physicians, techs, nurses and administration Buy in from all stakeholders Basic, in
Slide 14: Addressing Healthcare Challenges
Addressing Healthcare Challenges Overdue paradigm shift into the digital age 14 Safer Work Environment Safer Work Environment Reduce Cost Expand Access To Care Improve Efficiency Enhance Quality
Slide 15: Future of Cardiovascular Robotics
Future of Cardiovascular Robotics 15 The only platform for advanced capabilities Expanded compatibility, precise actuation, multiple device control, quick exchange. Advanced Device Manipulation Algorithms to guide peri - procedure lesion assessment, treatment plan, and device selection. Prescriptive
Slide 16: Technology Enablers
Technology Enablers 16 Third - party technologies that compliment robotics Advanced Imaging ▪ 3D Image Reconstruction ▪ CT Fractional Flow Reserve (FFR ) ▪ Angiographic FFR Data Integration ▪ Machine Learnings ▪ Descriptive and Prescriptive Data ▪ Algorithms Autonomous ▪ Sensors ▪ Mapping ▪ Closed L
Slide 17: Telestenting First-in-Human Study
Telestenting First - in - Human Study Study showed 86.4% technical success and 95% procedural success 17 REMOTE - PCI REMOTE - PCI Study explored feasibility of remote telestenting using a robotic system Single - center prospective observational study performed at Spectrum Health, Grand Rapids, MI 2
Slide 18: Vascular Robotic Clinical Roadmap
Vascular Robotic Clinical Roadmap Demonstrating excellence in multiple lesion types and anatomies Product Evolution Robotic system capability Exploratory Feasibility Expand Use NEURO PERIPHERAL PCI 18 STRUCTURAL CorPath 200 and CorPath GRX Systems are indicated for PCI. Only the CorPath 200 System i
Slide 19: Strategic Objectives
19 Corindus Vascular Robotics Strategic Objectives Near Term Mid to Long Term Mid to Long Term x Recurring revenue streams and NG3 system launch x Expansion into additional disease states (neurovascular and structural heart) x Global expansion and remote tele - proctoring, with specific focus on Chi
Slide 20: Financial Snapshot
1 As of December 31, 2016 2 As of September 30, 2016 3 Outstanding principal balance 4 Per our press release filed on January 17, 2017 Financial Snapshot Key Financial Metrics Cash and Cash Equivalents 1 $9.2 million Debt 2,3 $4.7 million Basic Shares Outstanding 2 119,025,221 Guidance Year Robotic
Slide 21: About Corindus Vascular Robotics
Corindus Vascular Robotics, Inc. is a global technology leader in robotic - assisted vascular interventions. The company's CorPath ® System is the first FDA - cleared medical device to bring robotic - assisted precision to percutaneous coronary interventions. With the CorPath System, Corindus Vascul
Corindus Vascular Robotics — Investor Presentation (March 2017) on 6ix